A Nested Case-Controlled Study Evaluating the Utility of Placental Protein 13 (PP13) In-vitro Diagnostic Kit as a Diagnostic Aiding Tool in Assessment of the Risk for Developing Preeclampsia Necessitating Delivery Before 37 Weeks (Early-preeclampsia) Based on First Trimester Blood Testing of Pregnant Women With Low and Unknown Risk
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Preeclampsia
- Sponsor
- Carl Weiner, MD
- Enrollment
- 431
- Locations
- 1
- Primary Endpoint
- Preeclampsia necessitating delivery at gestational age < 37 weeks including HELLP syndrome and eclampsia
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this study is to evaluate whether it is possible to detect changes in the concentration of PP13 in the blood of pregnant women who may go on to develop the complication of preeclampsia later on in the pregnancy, and if these changes can be detected early enough to allow early diagnosis and treatment for prevention of these complications and reduce their damage. This study will test if the PP13 biomarker during the first trimester of pregnancy has the ability to provide assessment of risk for the development of preeclampsia that necessitates delivery before 37 weeks gestation or can predict preeclampsia before 34 weeks gestation.
Detailed Description
After obtaining informed consent maternal demographics, vital signs, height, weight, medical history, pregnancy dating, dipstick for urine protein, previous lab results, nuchal translucency results and uterine artery Doppler results (if done) will be obtained. Blood for PP13 will be obtained at 7-13 weeks and optionally at 21-23 weeks. Hospitalization and delivery information will be obtained via a chart review for evidence of preeclampsia.
Investigators
Carl Weiner, MD
Professor and Chair, Obstetrics and Gynecology
University of Kansas Medical Center
Eligibility Criteria
Inclusion Criteria
- •Healthy, pregnant females
- •Singleton fetus at 7 0/7 to 13 6/7 weeks gestation
Exclusion Criteria
- •Multi-fetal pregnancy
- •Mental retardation
- •Known fetal anomaly or demise
- •BMI \> 35, serious medical condition
Outcomes
Primary Outcomes
Preeclampsia necessitating delivery at gestational age < 37 weeks including HELLP syndrome and eclampsia
Time Frame: 37 Weeks
Secondary Outcomes
- Maternal and Neonatal morbidity and mortality and very early preeclampsia necessitating delivery before 34 weeks(34 Weeks, At Delivery)